☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K For the transition period from _____ to _____ Commission File Number: 001-31885 Delaware 11-2644611 (I.R.S. Employer Identification No.) 5115 Ulmerton Road, Clearwater, FL 33760 (Address ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $14.2 million, a decrease of 3% compared to $14.7 million in Q4 2023 [7][23] - Gross profit for Q4 2024 increased to $9 million, with a gross profit margin of 63.0%, up from 60.9% in the prior year [25] - Net loss attributable to stockholders was $4.6 million or $0.12 per share for Q4 2024, compared to a net loss of $9.6 million or $0.28 per share in Q4 2023 [28] Business Segment Data and Key Metrics Changes - Advanced Energy segment revenue was flat at approximately $12.1 million, with a 30% increase compared to Q3 2024 [8][24] - OEM segment sales decreased by 16% to approximately $1.6 million in Q4 2024 compared to Q4 2023 [24] - Domestic revenue increased by 1% year-over-year to $10.6 million, while international revenue decreased by 8% to $3.7 million [25] Market Data and Key Metrics Changes - The aesthetic market has faced challenges due to the macroeconomic environment and the adoption of GLP-1 drugs, which have diverted discretionary spending [9][10] - The company believes that patients who have lost weight due to GLP-1 drugs will seek surgical solutions, positioning the Renuvion system favorably [11][12] Company Strategy and Development Direction - The company is focusing on the launch of the AYON Body Contouring System, expected in the second half of 2025, which integrates multiple surgical technologies [16][18] - Apyx Medical aims to capitalize on the growing demand for surgical aesthetics, particularly for patients experiencing skin laxity after significant weight loss [12][60] - A restructuring program was implemented to reduce U.S. workforce by nearly 25%, aiming for annualized cost savings of approximately $4.3 million [20][21] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the momentum in the Advanced Energy segment and the potential for growth in 2025 [8][9] - The company anticipates total revenue for 2025 to be in the range of $47.6 million to $49.0 million, reflecting a slight increase from 2024 [30] - Management noted that the aesthetic space is experiencing disruption due to the impact of GLP-1 drugs, which could benefit companies with the right technologies [62] Other Important Information - The company completed a registered direct offering with net proceeds of approximately $6.8 million to strengthen its balance sheet [21] - Cash and cash equivalents as of December 31, 2024, were $31.7 million, down from $43.7 million a year earlier [29] Q&A Session Summary Question: Confirmation of gross margin for 2025 - Management confirmed that they expect gross margins to be around 60% for 2025 [34][35] Question: Timing and revenue expectations for AYON - Management indicated that the guidance for AYON has not been updated despite the earlier submission for FDA approval, and revenue expectations remain conservative [40][41] Question: Changes in direct-to-consumer campaign and future outlook - Management highlighted the success of the DTC campaign and the importance of addressing the needs of patients experiencing skin laxity due to weight loss [50][52] Question: Domestic vs. international market performance - Management noted that the U.S. market is performing better due to early adoption of GLP-1 drugs, with expectations for similar trends internationally [56][58] Question: Adoption of GLP-1s and utilization of Renuvion - Management reported growth in handpiece sales in the U.S. and noted that surgical practices are adapting to treat patients with skin laxity effectively [66][70] Question: Upgrades for the Apyx One Console - Management stated that there is still a significant number of customers who need to upgrade to the Apyx One Console before AYON's launch [72][75]

APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 January 13, 2025 Date of Report (date of earliest event reported) (State or other jurisdiction of Delaware 001-31885 11-2644611 (I.R.S. Employer Identification No.) incorporation or organization) (Commission File Number) 5115 Ulmerton Road, Clearwater, Florida 3376 ...

The number of single-use handpiece units shipped in Q4 2024 exceeded expectations, increasing 5% overall and 20% in the U.S. compared to the same period last yearSubmitted a 510(k) premarket notification to the U.S. FDA for the AYON™ Body Contouring System ahead of schedule and preparing for a planned launch in the back half of 2025, pending clearanceManagement to host a conference call today at 8:30 a.m. ET CLEARWATER, Fla., March 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (“Apyx M ...

CLEARWATER, Fla., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ: APYX) (“Apyx Medical;” the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the fourth quarter and fiscal year 2024 will be released before the market opens on Thursday, March 13th. Management will host a conference call at 8:30 a.m. Eastern Time on Thursday, March 13th to discuss the results of the fourth q ...

CLEARWATER, Fla, Jan. 13, 2025 (GLOBE NEWSWIRE) -- Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported preliminary revenue results for the fourth quarter and full year ended December 31, 2024. Preliminary Fourth Quarter 2024 Revenue Summary: Total revenue expected to be in a range of approximately $14.1 to $14.3 million, representing a decrease of 4% to 3% year-over-year. Advanced ...

Focusing on advancing body contouring by providing the first all-in-one platform for the surgical suiteCLEARWATER, Fla., Jan. 06, 2025 (GLOBE NEWSWIRE) -- Apyx® Medical Corporation (NASDAQ:APYX) (“Apyx Medical”; the “Company”), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (the “FDA”) for the AYON Body Contouring System. The AYON Bod ...

Core Viewpoint - Apyx Medical Corporation is actively engaging with investors by attending the 15th Annual Craig-Hallum Alpha Select Conference on November 19, 2024, in New York City, highlighting its commitment to investor relations and market presence [1]. Company Overview - Apyx Medical Corporation specializes in advanced energy technology, focusing on innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion in the cosmetic surgery market and J-Plasma in the hospital surgical market [2]. - The Renuvion and J-Plasma technologies provide surgeons with the capability to deliver controlled heat to tissue, enhancing surgical outcomes, supported by over 90 clinical documents [2]. - The company also engages in OEM agreements with other medical device manufacturers, leveraging its expertise in unique waveforms [2].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission File Number: 001-31885 APYX MEDICAL CORPORATION (Exact name of registrant as specified in its charter) Delaware 11-2644611 (State or other ...

Financial Data and Key Metrics Changes - The company reported total revenue of $11.5 million for Q3 2024, a decrease of 4% compared to $12 million in Q3 2023 [16][22] - Advanced Energy products sales decreased 6% year-over-year to $9.3 million, primarily due to soft generator capital sales [16][22] - Gross profit for Q3 2024 decreased by $1 million or 13% to $7 million, with a gross profit margin of 60.5% compared to 66.6% in the prior year [23] - Net loss attributable to shareholders was $4.7 million or $0.14 per share, compared to $4.6 million or $0.13 per share in the prior year [25] Business Line Data and Key Metrics Changes - Disposable handpiece revenue grew 9% overall and 15% in the United States, now accounting for more than 60% of total Advanced Energy revenue [17][19] - OEM segment sales increased by 3% to approximately $0.1 million in Q3 2024 compared to Q3 2023, driven by increased sales volumes to existing customers [22] Market Data and Key Metrics Changes - The company noted that the macroeconomic environment and the introduction of GLP-1 drugs have negatively impacted procedural volumes, leading to a postponement of aesthetic procedures [16][18] - The company anticipates that the growing population on GLP-1 drugs will create a significant tailwind for Renuvion, the only FDA-approved solution for loose skin [19] Company Strategy and Development Direction - Apyx Medical is implementing an organizational restructuring, reducing its US workforce by nearly 25% to streamline operations and focus resources [7][9] - The company is developing the Ayon body contouring system, which integrates multiple technologies into a single device, aiming for FDA submission by the end of Q1 2025 and a launch in the second half of 2025 [20][31] - Apyx Medical plans to enhance its direct-to-consumer marketing strategy to increase awareness of Renuvion and educate patients on treatment options [19][38] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about returning to growth, citing the potential of the Ayon platform and the expected recovery in the capital equipment market [10][28] - The company anticipates total revenue for 2024 to be in the range of $46.6 million to $47.6 million, representing a decrease of approximately 11% to 9% year-over-year [28][31] Other Important Information - The company announced a $7 million registered direct cash investment from Nantahala Capital Management to strengthen its balance sheet [13][26] - Apyx Medical has amended its credit agreement with Perceptive Advisors, reducing revenue covenants and adding operating expense covenants for 2025 and 2026 [13][26] Q&A Session Summary Question: Where will the growth for Advanced Energy come from in 2025? - Management indicated that growth is expected to come from continued handpiece growth and some contribution from Ayon in the latter half of the year [33] Question: Can you elaborate on the Ayon product and its market potential? - Management described Ayon as a game changer that integrates various technologies, with a focus on making surgical procedures safer and more efficient [34][40] Question: How is the company positioning for growth in 2025 amidst changing market conditions? - Management highlighted an increase in direct-to-consumer marketing efforts and a focus on educating patients about treatment options [38] Question: What are the implications of the reduction in force? - The reduction was across the board, aimed at right-sizing the organization to focus on profitability [44] Question: Will Ayon cannibalize the Renuvion market? - Management clarified that Ayon will not replace Renuvion but will enhance the offerings for existing customers who have the Apyx One generator [39][40] Question: How quickly will the identified cost savings be implemented? - Management confirmed that the cost savings will be realized in the current quarter, with no additional one-time charges expected [49]